Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing
Q Ding, A Strong, KM Patel, SL Ng, BS Gosis… - Circulation …, 2014 - Am Heart Assoc
Q Ding, A Strong, KM Patel, SL Ng, BS Gosis, SN Regan, CA Cowan, DJ Rader, K Musunuru
Circulation research, 2014•Am Heart AssocRationale: Individuals with naturally occurring loss-of-function proprotein convertase
subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein
cholesterol levels and protection against cardiovascular disease. Objective: The goal of this
study was to assess whether genome editing using a clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated system can efficiently introduce loss-of-
function mutations into the endogenous PCSK9 gene in vivo. Methods and Results: We …
subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein
cholesterol levels and protection against cardiovascular disease. Objective: The goal of this
study was to assess whether genome editing using a clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated system can efficiently introduce loss-of-
function mutations into the endogenous PCSK9 gene in vivo. Methods and Results: We …
Rationale
Individuals with naturally occurring loss-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein cholesterol levels and protection against cardiovascular disease.
Objective
The goal of this study was to assess whether genome editing using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system can efficiently introduce loss-of-function mutations into the endogenous PCSK9 gene in vivo.
Methods and Results
We used adenovirus to express CRISPR-associated 9 and a CRISPR guide RNA targeting Pcsk9 in mouse liver, where the gene is specifically expressed. We found that <3 to 4 days of administration of the virus, the mutagenesis rate of Pcsk9 in the liver was as high as >50%. This resulted in decreased plasma PCSK9 levels, increased hepatic low-density lipoprotein receptor levels, and decreased plasma cholesterol levels (by 35–40%). No off-target mutagenesis was detected in 10 selected sites.
Conclusions
Genome editing with the CRISPR–CRISPR-associated 9 system disrupts the Pcsk9 gene in vivo with high efficiency and reduces blood cholesterol levels in mice. This approach may have therapeutic potential for the prevention of cardiovascular disease in humans.
Am Heart Assoc
